Pricing Log in Create free account

Ovid Therapeutics (OVID) vs REGENXBIO Inc. (RGNX)

Ovid Therapeutics and REGENXBIO Inc. are both Biotechnology companies. Ovid Therapeutics and REGENXBIO Inc. are of similar size ($503.9M and $487.2M). Ovid Therapeutics grew revenue faster over the last twelve months: 1,333.4% against −4.59%. REGENXBIO Inc. has the higher net margin (−113.9% vs −439.1%) and the higher return on invested capital (0.00% vs −35.1%). Across the 18 metrics below, Ovid Therapeutics leads on 10 and REGENXBIO Inc. on 8.

Valuation

Metric OVID RGNX Biotechnology median
P/E n/m n/m 10.60
P/S 72.14 3.21 9.40
P/B 2.70 3.33 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 58.65 1.61 9.02
Earnings yield (7.85%) (42.52%) (32.88%)
Free cash flow yield (9.69%) (31.38%) (23.13%)

Profitability

Metric OVID RGNX Biotechnology median
Gross margin 100.00% 87.54% 68.51%
Operating margin (742.97%) (95.68%) 0.00%
Net margin (439.11%) (113.85%) 0.00%
Free cash flow margin (697.30%) (100.58%) 0.00%
Return on equity (25.97%) (113.24%) (51.96%)
Return on assets (22.30%) (35.36%) (46.06%)
Return on invested capital (35.11%) 0.00% 0.00%

Growth

Metric OVID RGNX Biotechnology median
Revenue growth (TTM) 1,333.39% (4.59%) 6.76%
EPS growth (last fiscal year) 37.84% 18.08% 29.88%
Revenue growth, 5-year CAGR (10.48%) 1.97% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OVID RGNX Biotechnology median
Debt to equity 0.05 0.00 0.00
Current ratio 12.39 4.74 4.97
Net debt to EBITDA 1.37 1.58 1.01

Dividend

Metric OVID RGNX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric OVID RGNX Biotechnology median
Market cap 503.87m 487.18m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack